|Bid||7.16 x 2200|
|Ask||7.17 x 2200|
|Day's range||6.67 - 7.25|
|52-week range||3.82 - 19.39|
|Beta (5Y monthly)||2.37|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.50|
Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
The biopharmaceutical company did not report any news, but perhaps the market is responding to comments made by Mad Money host Jim Cramer regarding Sorrento Therapeutics on his show on Friday, April 23. Jim Cramer's comments hardly painted a bullish picture of Sorrento Therapeutics. During the lightning round bell -- when he gives quick and short answers to callers' questions on various stocks -- Cramer said the following: "There'll be a news release and it'll spike 3-4 points ... and that'll give you a chance to get out."
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE).